Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IONS Stock Forecast 2026-2027
$74.87
Current Price
$12.51B
Market Cap
Buy 17
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to IONS Price Targets
+60.3%
To High Target of $120.00
+36.2%
To Median Target of $102.00
-37.2%
To Low Target of $47.00
IONS Price Momentum
-2.5%
1 Week Change
+5.5%
1 Month Change
+162.6%
1 Year Change
-5.4%
Year-to-Date Change
-13.7%
From 52W High of $86.74
+168.4%
From 52W Low of $27.90
📊 TOP ANALYST CALLS
Did IONS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ionis is one of their latest high-conviction picks.
Latest IONS Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, IONS has a bullish consensus with a median price target of $102.00 (ranging from $47.00 to $120.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $74.87, the median forecast implies a 36.2% upside. This outlook is supported by 17 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mitchell S. Kapoor at HC Wainwright & Co., projecting a 60.3% upside. Conversely, the most conservative target is provided by Jessica Fye at JP Morgan, suggesting a 37.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IONS Analyst Ratings
17
Buy
6
Hold
0
Sell
IONS Price Target Range
Low
$47.00
Average
$102.00
High
$120.00
Current: $74.87
Latest IONS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IONS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | B of A Securities | Jason Gerberry | Buy | Maintains | $111.00 |
| Mar 26, 2026 | Barclays | Eliana Merle | Overweight | Maintains | $106.00 |
| Mar 25, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $120.00 |
| Mar 25, 2026 | Needham | Joseph Stringer | Buy | Maintains | $105.00 |
| Mar 3, 2026 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $104.00 |
| Feb 27, 2026 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $100.00 |
| Feb 26, 2026 | Stifel | Paul Matteis | Hold | Maintains | $77.00 |
| Feb 26, 2026 | Needham | Joseph Stringer | Buy | Maintains | $103.00 |
| Feb 6, 2026 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $87.00 |
| Jan 5, 2026 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $100.00 |
| Dec 17, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $95.00 |
| Dec 15, 2025 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $100.00 |
| Dec 9, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $97.00 |
| Nov 10, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $110.00 |
| Nov 4, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $77.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $100.00 |
| Oct 30, 2025 | Raymond James | Gary Nachman | Strong Buy | Reiterates | $89.00 |
| Oct 30, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $94.00 |
| Oct 30, 2025 | Needham | Joseph Stringer | Buy | Maintains | $90.00 |
| Oct 30, 2025 | Barclays | Gena Wang | Overweight | Maintains | $95.00 |
Ionis Pharmaceuticals, Inc. (IONS) Competitors
The following stocks are similar to Ionis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ionis Pharmaceuticals, Inc. (IONS) Financial Data
Ionis Pharmaceuticals, Inc. has a market capitalization of $12.51B with a P/E ratio of -31.5x. The company generates $943.71M in trailing twelve-month revenue with a -40.4% profit margin.
Revenue growth is -10.3% quarter-over-quarter, while maintaining an operating margin of -105.5% and return on equity of -70.8%.
Valuation Metrics
Market Cap
$12.51B
Enterprise Value
$12.44B
P/E Ratio
-31.5x
PEG Ratio
-0.3x
Price/Sales
13.3x
Growth & Margins
Revenue Growth (YoY)
-10.3%
Gross Margin
+96.1%
Operating Margin
-105.5%
Net Margin
-40.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.7%
Current Ratio
3.8x
Debt/Equity
534.8x
ROE
-70.8%
ROA
-7.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ionis Pharmaceuticals, Inc. (IONS) Business Model
About Ionis Pharmaceuticals, Inc.
What They Do
Biotechnology company focused on RNA-targeted therapies.
Business Model
The company makes money through product sales, royalties from partnered drugs, and research and development collaborations with major pharmaceutical partners such as Biogen and AstraZeneca. Its proprietary antisense technology platform allows it to create novel therapeutics for challenging diseases, contributing to a diverse revenue stream.
Additional Information
Ionis Pharmaceuticals has a strong pipeline of investigational medicines targeting various conditions, including cardiovascular and neurological diseases. Key marketed products include TRYNGOLZA and DAWNZERA, with additional revenues from royalties on successful therapies like SPINRAZA. Established in 1989 and based in Carlsbad, California, the company is recognized for its innovative approach to addressing unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,402
CEO
Dr. Brett P. Monia Ph.D.
Country
United States
IPO Year
1991
Website
www.ionis.comIonis Pharmaceuticals, Inc. (IONS) Latest News & Analysis
Latest News
Quick Summary
Ionis Pharmaceuticals will host a live webcast on April 29 at 8:30 a.m. ET to discuss its Q1 2026 financial results and program updates. Access the webcast at their investor relations site.
Why It Matters
Ionis Pharmaceuticals' upcoming webcast on Q1 2026 results may reveal financial performance and updates on key programs, influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
21 days ago
Quick Summary
Biogen's High Dose Regimen of SPINRAZA has received FDA approval for spinal muscular atrophy treatment, following positive DEVOTE study results. Availability in the U.S. is expected soon.
Why It Matters
Approval of the High Dose Regimen of SPINRAZA boosts Biogen's product portfolio, potentially increasing revenue and market share in the SMA treatment space, positively impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago; investors should monitor upcoming developments and stock performance for future insights.
Why It Matters
Earnings reports influence stock performance and investor sentiment. Upcoming developments for Ionis Pharmaceuticals may affect share price, making it crucial for investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Ionis Pharmaceuticals (NASDAQ:IONS) has gained 137.52% over the past year but has declined 6.12% year-to-date, trading near $72.70, 7.20% below its one-month high.
Why It Matters
Ionis Pharmaceuticals' significant past gain highlights strong performance potential, but the recent pullback may indicate volatility and present buying opportunities or caution for investors.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
25 days ago
Quick Summary
Hypertriglyceridemia is defined by elevated triglyceride levels in the blood, which can impact health and may have implications for certain industries, such as pharmaceuticals and healthcare.
Why It Matters
Rising hypertriglyceridemia rates can drive demand for treatments, impacting pharmaceutical stocks and healthcare investments as companies develop solutions.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
IONS receives FDA priority review for zilganersen targeting Alexander disease, with a decision expected by September 22, 2026, based on strong phase III trial results.
Why It Matters
IONS' FDA priority review for zilganersen boosts its market potential in treating Alexander disease, signaling strong growth prospects and increased investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IONS Stock
What is Ionis Pharmaceuticals, Inc.'s (IONS) stock forecast for 2026?
Based on our analysis of 34 Wall Street analysts, Ionis Pharmaceuticals, Inc. (IONS) has a median price target of $102.00. The highest price target is $120.00 and the lowest is $47.00.
Is IONS stock a good investment in 2026?
According to current analyst ratings, IONS has 17 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $74.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IONS stock?
Wall Street analysts predict IONS stock could reach $102.00 in the next 12 months. This represents a 36.2% increase from the current price of $74.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ionis Pharmaceuticals, Inc.'s business model?
The company makes money through product sales, royalties from partnered drugs, and research and development collaborations with major pharmaceutical partners such as Biogen and AstraZeneca. Its proprietary antisense technology platform allows it to create novel therapeutics for challenging diseases, contributing to a diverse revenue stream.
What is the highest forecasted price for IONS Ionis Pharmaceuticals, Inc.?
The highest price target for IONS is $120.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 60.3% increase from the current price of $74.87.
What is the lowest forecasted price for IONS Ionis Pharmaceuticals, Inc.?
The lowest price target for IONS is $47.00 from Jessica Fye at JP Morgan, which represents a -37.2% decrease from the current price of $74.87.
What is the overall IONS consensus from analysts for Ionis Pharmaceuticals, Inc.?
The overall analyst consensus for IONS is bullish. Out of 34 Wall Street analysts, 17 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $102.00.
How accurate are IONS stock price projections?
Stock price projections, including those for Ionis Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 3:01 AM UTC